ABSTRACT S32504 [(ϩ)-trans-3,4,4a,5,6,10b-hexahydro-9-carbamoyl-4-propyl-2H-naphth Particular attention has been devoted to D 3 receptors that display patterns of ligand recognition and intracellular coupling similar to those of closely related D 2 receptors (Levant, Article, publication date, and citation information can be found at
1997; Vallone et al., 2000) , of which short (D 2S ) and long (D 2L ) isoforms are predominantly localized pre-and postsynaptically, respectively, relative to dopaminergic pathways (Usiello et al., 2000; Centonze et al., 2002) . Although D 2 receptors appear to be of broad functional significance, the precise role of D 3 receptors has proven difficult to identify inasmuch as conventional dopaminergic ligands such as the antagonist haloperidol and the agonist apomorphine interact indiscriminately with both D 2 and D 3 sites (Levant, 1997; Vallone et al., 2000; Joyce, 2001; Millan et al., 2002) . Nevertheless, crucial insights into the functional significance of D 3 versus D 2 receptors have recently been provided by: first, use of the preferential D 2 versus D 3 receptor antagonist L741,626, together with highly selective D 3 versus D 2 receptor antagonists, such as GR218,231, S33084, and SB277,011 (Millan et al., 2000a,b; Crider and Scheideler, 2001) ; second, characterization of mice genetically deprived of either D 2 and/or D 3 receptors (Sibley, 1999) ; and third, use of antisense probes directed against D 3 or D 2 receptors (Ekman et al., 1998) .
Accordingly, a consensus has emerged that inhibitory D 2 autoreceptors predominate over their D 3 counterparts on dopaminergic pathways (Joyce, 2001) , although postsynaptic populations of D 3 receptor may modulate the activity of ascending dopaminergic pathways via a feedback loop (Millan et al., 2000a,b; Zapata et al., 2001; Joseph et al., 2002) . At the postsynaptic level, broadly distributed, cerebral populations of D 2 receptors fulfill diverse roles in, for example, the control of mood and motor function (Picetti et al., 1997; Vallone et al., 2000) . Dopamine D 3 receptors show a more restricted distribution, being concentrated in limbic regions (Stanwood et al., 2000; Joyce, 2001) . These populations are involved in the control of emotion and reward, actions of relevance to depressive and psychotic states as well as drug abuse (Picetti et al., 1997; Joyce, 2001) . Of particular interest is the contrasting influence of postsynaptic D 2 and D 3 receptors upon motor behavior. There is, thus, unequivocal evidence for a facilitatory influence of striatal and limbic populations of D 2 receptors upon motor function (Sibley, 1999; Joyce, 2001) . On the other hand, D 3 sites, which are primarily localized on different classes of striatal neurons compared with their D 2 counterparts (Joyce, 2001) , may exert an opposite, tonic, inhibitory influence upon locomotion (Waters et al., 1993) . However, this remains disputed and the significance of D 3 receptors to the beneficial (restoration of motor function) and deleterious (induction of dyskinesia) actions of antiparkinsonian agents remains controversial (Ekman et al., 1998; Béz-ard et al., 2003; Millan et al., 2004c) . The role of D 3 compared with D 2 receptors in the neuroprotective properties of dopaminergic agonists in Parkinson's patients (Whone et al., 2003) also remains unclear. Nevertheless, as discussed in the accompanying paper (Millan et al., 2004b) , D 3 sites participate in the ability of dopamine D 3 /D 2 receptor agonists to protect dopaminergic neurons from neurotoxic damage in rodents (Joyce et al., 2003; Ramirez et al., 2003) .
In light of the above comments, there is considerable interest in novel ligands at D 3 and/or D 2 receptors for the improved treatment of psychiatric and neurological disorders (Crider and Scheideler, 2001) . Although many agonists at D 2 /D 3 sites have been described, the majority potently interact with other classes of dopaminergic, adrenergic, and serotonergic receptors. Such actions modify their functional profiles and limit their utility as pharmacological tools for exploration of the significance of D 3 and D 2 sites (Joyce, 2001; Millan et al., 2002; Newman-Tancredi et al., 2002a,b) . Indeed, the indolinone, ropinirole (Fig. 1) , remains one of the few genuinely selective D 2 /D 3 agonists to be therapeutically employed in the management of PD (Coldwell et al., 1999; Matheson and Spencer, 2000; Rascol et al., 2000) .
The chemically novel naphtoxazine derivative, S32504 ( Fig. 1) , is of particular interest since, as described in this series of papers (Millan et al., 2004a,b) , it behaves as a highly selective agonist at D 3 /D 2 receptors and shows pronounced activity in experimental models of potential antiparkinsonian, neuroprotective, and antidepressant properties. Employing a complementary cellular, neurochemical, and electrophysiological approach, the present study characterizes: 1) the binding profile of S32504; 2) its influence upon transduction mechanisms controlled by hD 3 , hD 2L , hD 2S , and hD 4 receptors; 3) its modulation of the electrical, synthetic, and DA-releasing activity of ascending dopaminergic pathways; and 4) its (comparatively weak) actions at serotonin (5-HT) 1A and 5-HT 2A receptors, which are implicated in the influence of many antiparkinsonian agents upon motor function, mood, and cognition (Gresch and Walker, 1999; Bibbiani et al., 2001; Millan et al., 2002; Newman-Tancredi et al., 2002a,b) . To underpin the specificity of actions of S32504, its effects were compared with those of its less active enantiomer S32601. Furthermore, its actions were systematically compared with those of ropinirole. Finally, employing haloperidol, S33084, and L741,626 (see above citations; Millan et al., 2000a) , we examined the role of D 3 compared with D 2 receptors in the actions of S32504. ature 22°C. The incubation period was 40 min for hD 3 , hD 2S , and hD 2L sites and 20 min for hD 4 sites. The buffer contained Hepes (20 mM), NaCl (150 mM for hD 3 and l00 mM for hD 2S , hD 2L , and hD 4 receptors), guanosine diphosphate (3 M), and MgCl 2 (3 mM for D 3 and 10 mM for other receptors). Membranes were incubated with drug for 15 min before the addition of [
35 S]GTP␥S. Agonist efficacies are expressed as a percentage of the effect observed with maximally effective concentrations of DA (3 M) . Experiments were terminated by rapid filtration through Unifilter-96 GF/B filters (PerkinElmer Life and Analytical Sciences, Boston, MA) using a filtermate harvester (PerkinElmer Life and Analytical Sciences). Radioactivity retained on the filters was determined by liquid scintillation counting using a Top Count microplate scintillation counter (PerkinElmer Life and Analytical Sciences). Data are expressed as means Ϯ S.E.M. of at least three independent determinations performed in triplicate.
Determination of Drug Efficacies at hD 3 and hD 2L Receptors Coupled to G␣ i3 by Antibody Capture Assay/Scintillation Proximity Assay (SPA). G␣ i3 subunit stimulation by CHO-transfected hD 3 and hD 2L receptors was quantified using SPA procedures essentially as previously described for coupling of 5-HT 2C receptors . In brief, [
35 S]GTP␥S binding was carried out as described above for conventional filtration protocols but in 96-well optiplates (PerkinElmer Life and Analytical Sciences). At the end of the incubation period, 20 l of NP40 (0.27% final concentration) was added to each well, and the plates were incubated with gentle agitation for 30 min. Thereafter, 10 l of anti-G␣ i3 (0.87 g/ml final dilution) was added and incubation continued for a further 30 min. SPA beads coated with secondary anti-mouse antibodies (Amersham Biosciences UK, Ltd., Little Chalfont, Buckinghamshire, UK) were added in a volume of 50 l and plates incubated for 3 h with gentle agitation. The plates were then centrifuged (10 min at 1300g) and radioactivity quantitated on a Top Count microplate scintillation counter. Membranes were incubated with agonists alone or with S32504 plus antagonist for 15 min before the addition of [
35 S]GTP␥S. The efficacies of S32504 and ropinirole are expressed relative to those of DA, which was tested at a maximally effective concentration (1 M for hD 3 and 10 M for hD 2L ) in each experiment. Antagonist K B values for inhibition of S32504-stimulated G␣ i3 subunit stimulation were calculated according to the Cheng-Prusoff equation: K B ϭ IC 50 /(1 ϩ (agonist/EC 50 )), where IC 50 is IC 50 of antagonist, agonist is concentration of S32504, and EC 50 is EC 50 of S32504 alone. All data are expressed as means Ϯ S.E.M. of at least three independent determinations, each performed in triplicate.
Determination of Drug Efficacies at hD 3 and hD 2L Receptors by Induction of Mitogen-Activated Protein (MAP) Kinase Phosphorylation. CHO cells expressing hD 3 or hD 2L receptors were grown in 24-well plates until 90% confluent, and MAP kinase phosphorylation was determined as previously described . In brief, the cells were washed once with serum-free medium and incubated overnight in this medium. Drugs were diluted in the serum-free medium and added to cells to obtain the appropriate final concentration. For antagonist studies, cells were preincubated for 20 min with the antagonist at concentrations indicated and then exposed to S32504 for a further 5 min. At the end of the incubation period, 0.25 ml per well of Laemmli sample buffer containing 200 mM of dithiothreitol was added. Whole-cell lysates were boiled for 3 min at 95°C. Cell extracts (14 l) were loaded onto 15-well 10% polyacrylamide gels, and "fully" activated MAP kinase was revealed using a monoclonal antibody specifically raised against the phosphorylated pp42 MAP-KINASE (ERK 2) and pp (ERK 1) forms on both threonine and tyrosine residues (NanoTools, Denzlingen, Germany), followed by chemiluminescence detection with horseradish peroxidase as a secondary antibody (Amersham, Les Ulis, France). Immunoblots shown are from representative experiments repeated at least three times with comparable results. Autoradiograms were analyzed by computerized densitometry using AIS software (Imaging Research, St. Catherines, ON, Canada), and phosphorylated MAP kinase was quantified. Isotherms were analyzed by nonlinear regression using PRISM (Graphpad Software Inc.). The efficacies of S32504 and ropinirole are expressed relative to those of DA, which was tested at a maximally effective concentration (0.1 M for hD 3 and 1 M for hD 2L ) in each experiment. K B values of antagonists for inhibition of S32504-stimulated MAP kinase phosphorylation were calculated according to the Cheng-Prusoff equation (see above). Determination of Drug Efficacies at h5-HT 1A Receptors and at h5-HT 2A Receptors. The efficacy of S32504 at CHO-expressed h5-HT 1A receptors was determined by a total [
35 S]-GTP␥S binding procedure as described previously . The efficacy of S32504 at CHO-transfected h5-HT 2A receptors was determined as described in detail elsewhere (Cussac et al., 2002c ) by depletion of membrane-bound [ 3 H]phosphatidylinositol ([ 3 H]PI), a measure of phospholipase C activation. Efficacy at h5-HT 2A receptors was also determined by G q activation employing the same SPA protocol used for activation of G q -coupled h5-HT 2C receptors . The efficacies of S32504 and ropinirole are expressed relative to those of 5-HT, which was tested at a maximally effective concentration (10 M) in each experiment. K B values of antagonists for inhibition of agonist actions of S32504 were calculated according to the Cheng-Prusoff equation (see above). All data are expressed as means Ϯ S.E.M. of at least three independent determinations performed in triplicate. Animals. Unless otherwise specified below, studies employed male Wistar rats of 180 to 250 g (Iffa Credo, L'Arbresele, France) housed in sawdust-lined cages with unrestricted access to standard chow and water. There was a 12-h light/dark cycle with lights on at 7:30 AM. Laboratory temperature and humidity were 21 Ϯ 0.5°C and 60 Ϯ 5%, respectively. Animals were adapted to laboratory conditions for at least 1 week prior to testing. All animals use procedures conformed to international European ethical standards (86/609-EEC) and the French National Committee (décret 87/848) for the care and use of laboratory animals.
Influence of Drugs upon the Electrical Activity of Dopaminergic Compared with Serotonergic and Adrenergic Cell Bodies. The influence of drugs upon the firing rate of ventrotegmental area (VTA)-localized dopaminergic cell bodies compared with dorsal raphe nucleus (DRN)-localized serotonergic and locus coeruleus-localized adrenergic perikarya was determined in anesthetized jpet.aspetjournals.org rats as described previously (Millan et al., 2000a) . In brief, following anesthesia with chloral hydrate (400 mg/kg, i.p.), rats were placed in a stereotaxic apparatus, and a tungsten microelectrode was lowered into the VTA, DRN, or locus coeruleus. Coordinates were as follows: VTA, AP ϭ Ϫ5.5 from bregma, L ϭ 0.8, and H ϭ Ϫ7/Ϫ8.5 from dura; DRN, AP ϭ Ϫ7.8 from bregma, L ϭ 0.0, and H ϭ Ϫ5.5/Ϫ6.5 from dura; and locus coeruleus, AP ϭ Ϫ1.0 from zero, L ϭ 1.2, and H ϭ Ϫ5.5/6.0 from dura. Neurons in each structure were characterized by their distinctive wave form and their discharge rhythm (Millan et al., 2000b , and striatum (DA and 5-HT) was performed as previously described (Millan et al., 2000a) . Guide cannulae were implanted under pentobarbital anesthesia (60 mg/kg, i.p.) 1 week before experimentation at the following coordinates: FCX, AP ϭ ϩ2.2 from bregma, L ϭ Ϯ0.6, and H ϭ Ϫ0.2 from dura; nucleus accumbens, AP ϭ ϩ0.8 from bregma, L ϭ ϩ0.6, and H ϭ Ϫ4.5 from dura; and striatum, AP ϭ ϩ0.5 from bregma, L ϭ Ϫ2.8, and H ϭ Ϫ3.0 from dura. On the test day, a cuprophane CMA/11 probe (4 mm in length for the FCX and striatum, 2 mm in length for nucleus accumbens, and, in each case, 0.24 mm of outer diameter) was lowered into position. Three basal samples of 20 min each were taken. Vehicle, S32504, or ropinirole were administered s.c., and samples were taken for an additional 3 h. In the antagonist experiments of DA release (nucleus accumbens and striatum), haloperidol, L741,626, S33084, or vehicle were injected, followed, 20 min later, by S32504 (0.63 mg/kg, s.c.) or vehicle. In the antagonist experiments of 5-HT release (striatum), the selective 5-HT 1A receptor antagonist WAY100,635 (0.63 mg/kg, s.c.) or vehicle were injected before S32504 (10.0 mg/kg, s.c.). DA, 5-HT, and NA levels were quantified by high-performance liquid chromatography followed by coulometric detection. The assay limit of sensitivity was 0.1 to 0.2 pg/sample for DA, 5-HT, and NA in each case. Data were analyzed by ANOVA with sampling time as the repeated within-subject factor.
Influence of Drugs upon the Turnover of Dopamine Compared with 5-HT. As previously described (Millan et al., 2000a) , the ratio of levels of the DA metabolite, dihydroxyphenylacetic acid (DOPAC), to those of DA were determined in projection targets of the mesocortical pathway (FCX), the mesolimbic pathway (nucleus accumbens and olfactory tubercles), and the nigro-striatal pathway (striatum). The ratio of levels of the 5-HT metabolite, 5-hydroxyindole-acetic acid (5-HIAA), to those of 5-HT were also determined in these structures. The influence of S32504, ropinirole, and vehicle were evaluated 30 min following their administration. Tissue levels of DOPAC, DA, 5-HIAA, and 5-HT were determined by high-performance liquid chromatography and electrochemical detection. DOPAC/DA and 5-HIAA/5-HT ratios were expressed relative to those of vehicle values (defined as 100%). Data were analyzed by ANOVA followed by Dunnett's test.
Drugs. In general, full dose (concentration)-response curves were generated for S32504 and ropinirole. Dose (concentration)-response relationships were also established for antagonists, the dose ranges of which were based upon our previous characterization of selective actions at their respective targets (Millan et al., 1998 (Millan et al., , 2000a (Millan et al., ,b, 2004c Silverdale et al., 2002) . All drug doses are in terms of the base. Drugs were dissolved in sterile water, if necessary, plus a few drops of lactic acid, and pH adjusted to as close to normality (Ͼ5.0) as possible. Unless otherwise specified, drugs were injected s.c. in an injection volume of 1 ml/kg. Drug structures, sources, and salts were as follows. Haloperidol (Sigma, St. Quentin Fallevier, France) and L741,626 (Tocris Cookson Inc., Bristol, UK). S33084 and MDL100,907 were synthesized by G. Lavielle (Institut de Recherches Servier, Paris, France). Ropinirole HCl, WAY100,635 HCl, S31411, its (ϩ)enantiomer S32504, and its (Ϫ)enantiomer S32601 were synthesized by J.-L. Peglion (Institut de Recherches Servier).
Results
Binding Profile of S32504 Compared with S32601, S31411, and Ropinirole at hD 3 , hD 2L , and hD 2S Receptors. In an initial series of experiments, the binding profile of (ϩ)S32504 was compared with that of its enantiomer (Ϫ)S32601 and with that of their racemic form, (ϩ)S31411, at cloned, recombinant, CHO-transfected hD 3 , hD 2S , and hD 2L receptors. Racemic S31411 concentration-dependently occupied hD 3 receptors and, at higher concentrations, hD 2S and hD 2L receptors. This profile was potently mimicked by S32504, whereas S32601 displayed only low affinity for hD 3 , hD 2S , and hD 2L sites. On this basis, S32504 was selected as the isomer for intensive study, whereas S32601 served as a reference ligand for confirmation of the enantioselectivity (stereoselectivity) and specificity of its functional actions in vitro and in vivo. As documented previously , ropinirole likewise behaves as a preferential ligand of hD 3 compared with hD 2L and hD 2S receptors, although it is less potent than S32504 ( Fig. 2 ; Table 1 ).
Binding Profile of S32504 at Other Dopaminergic Receptor Subtypes. Compared with hD 3 receptors, the affinity of S32504 for cloned hD 4 receptors was very weak (Ͼ500-fold lower). Indeed, in contrast to hD 3 , hD 2L , and hD 2S receptors (see above), the affinity of S32504 for hD 4 receptors was lower than that of ropinirole 50 , 5.22 Ϯ 0.10) and efficacy (28 Ϯ 4%) of S32504 at these sites was low. This low activity was confirmed by studies of racemic S31411, which yielded a pEC 50 of 5.26 Ϯ 0.14 and an E max of 7.5% (not shown). S32601 was inactive (pEC 50 Ͻ 5.0). S32504 is, thus, a less efficacious ligand than ropinirole at hD 4 receptors : pEC 50 ϭ 5.54 Ϯ 0.06 and E max ϭ 74 Ϯ 2% ( Fig. 3; Table  1 for analyses. The data in panel E have been documented elsewhere in tabular form (Table 3) , whereas L741,626 (pK B , 7.66 Ϯ 0.1) was less active. These pK B values correlate well with their pK i values for hD 3 sites (Table 3) (Millan et al., 2000a) . Dopamine (though less potently) also elicited a marked and concentration-dependent 2-fold elevation in [
35 S]GTP␥S binding at hD 2L receptor-coupled G␣ i3 with a pEC 50 of 6.22 Ϯ 0.04. Its actions were mimicked by S32504 and ropinirole with pEC 50 values/percent efficacies of 6.63 Ϯ 0.10/51 Ϯ 1% and 6.59 Ϯ 0.06/54 Ϯ 5%, respectively (Table 2) . Haloperidol and L741,626, which did not influence basal [
35 S]GTP␥S binding (not shown), concentration dependently and potently blocked the action of S32504 at hD 2L sites with pK B values of 9.44 Ϯ 0.09 and 8.42 Ϯ 0.07, respectively. S33084, which was likewise inactive alone, less potently (pK B , 7.7 Ϯ 0.03) blocked the action of S32504 at hD 2L receptors (Table 3) . These pK B values for haloperidol, L741,626, and S33084 correlated well with their affinities for hD 2L receptors (Millan et al., 2000a) (Table 3) .
Activation of MAP Kinase Coupled to hD 3 and hD 2L Receptors. At hD 3 receptors, corroborating our previous study , DA evoked a marked increase in MAP kinase phosphorylation with a pEC 50 of 7.51 Ϯ 0.09 ( Fig. 5 ; Tables 2 and 3 ). S32504 and ropinirole mimicked this action of DA with pEC 50 values of 8.45 Ϯ 0.15 and 8.51 Ϯ 0.11, respectively, and E max values of 90 Ϯ 6% and 80 Ϯ 8%, respectively ( Table 2 ). The induction of MAP kinase phosphorylation by S32504 was concentration dependently suppressed by haloperidol and S33084 with pK B values of 9.83 Ϯ 0.07 and 9.27 Ϯ 0.2, respectively (Table 3) . At hD 2L receptors, DA elicited a pronounced induction of MAP kinase phosphorylation with a pEC 50 of 8.08 Ϯ 0.03. S32504 likewise potently activated MAP kinase with a similar E max (100 Ϯ 6%) and a pEC 50 of 8.59 Ϯ 0.15 (Table 2 ). This effect of S32504 was reproduced by ropinirole with a pEC 50 of 8.21 Ϯ 0.07 and an E max of 98 Ϯ 2% (Table 2) . Haloperidol and L741,626 concen- (Table 3) .
Binding Profile of S32504 to Nondopaminergic Receptors. Compared with hD 3 receptors, S32504 revealed modest affinity for cloned h5-HT 1A receptors, and it also showed modest affinity for native (rat) hippocampal 5-HT 1A receptors: pK i , 5.98 Ϯ 0.16. The affinity of S32504 for h5-HT 1B sites was low, but it showed modest affinity for h5-HT 1D and h5-HT 7 sites (Table 4) . For h5-HT 2A and h5-HT 2B receptors, the affinity of S32504 was weak, whereas it had low affinity for h5-HT 2C receptors. For all other classes of 5-HT receptor examined (5-HT 3 , 5-HT 4 , 5-HT 5A , and 5-HT 6 ), S32504 and ropinirole revealed negligible (pK i , Ͻ 5.0) affinity. S32504 displayed low affinity for native, rat, cortical ␣ 2D -adrenoceptors and cloned, h␣ 2A -, h␣ 2B -, and h␣ 2C -adrenoceptors. At native, rat, cortical ␣ 1 -adrenoceptors and cloned h␣ 1A -, h␣ 1B -, and h␣ 1D -adrenoceptors, as well as cloned h␤ 1 -and ␤ 2 -adrenoceptors, the affinity of S32504 was negligible (pK i values, Ͻ5.0). Neither S32504 nor ropinirole recognized (pK i values, Ͻ5.0) cloned hNA or h5-HT transporters labeled with (Fig. 6 ). This action was weakly mimicked by S32504 with a pEC 50 of 5.5 and an E max of 70% (data not shown), indicating that it behaves as a low potency partial agonist at these sites. At h5-HT 2A receptors, 5-HT also potently (pEC 50 , 7.56 Ϯ 0.06) and markedly (1.5-fold) enhanced [
35 S]GTP␥S binding to G␣ q as determined by a SPA procedure. This effect was weakly (pEC 50 , 5.23 Ϯ 0.04) mimicked by S32504 with an E max of 79 Ϯ 2%, confirming its weak partial agonist properties at h5-HT 2A sites. This action of S32504 was concentrationdependently abolished by the selective 5-HT 2A receptor antagonist, MDL100,907, with a pK B of 9.47 Ϯ 0.11. Modulation of the Electrical Activity of Dopaminergic Compared with Serotonergic and Noradrenergic Cell Bodies. By analogy to racemic S31411 and in distinction to its enantiomer S32601, S32504 dose-dependently and completely abolished the electrical activity of ventrotegmental dopaminergic perikarya in anesthetized rats (Fig. 7) . The ID 50 values were 0.57 and 1.15 g/kg, i.v. for S32504 and S31411, respectively; S32601 did not attain 50% inhibition at the highest dose (64 g/kg, i.v.) evaluated, so no ID 50 was determined. The inhibitory action of S32504 was associated with a reduction in the number of bursts emitted. Haloperidol completely reversed these actions of S32504. Only doses far in excess of those required to markedly suppress the firing rate of dopaminergic neurons reduced the electrical activity of serotonergic neurons of the DRN, an action blocked by the selective 5-HT 1A antagonist WAY100,635. nergic perikarya even at doses markedly higher than those inhibiting dopaminergic neurons. Modulation of Extracellular Levels of DA Compared with 5-HT and NA. In the FCX of freely moving rats, S32504 elicited a pronounced, sustained, and dose-dependent diminution in dialysis levels of DA, whereas levels of 5-HT and NA were not significantly modified at equivalent doses (Fig. 8) . Ropinirole exerted a similar pattern of selective influence upon levels of DA compared with 5-HT and NA in this structure (Fig. 8) . S32504 and ropinirole also potently and dose dependently suppressed extracellular levels of DA in the nucleus accumbens and striatum (Fig. 9) . In the presence of haloperidol or the preferential D 2 receptor antagonist L741,626, which elevated levels of DA in the nucleus accumbens and striatum, the influence of S32504 upon DA levels was abolished (Figs. 10 and 11) . In contrast, the selective D 3 receptor antagonist S33084, which was ineffective alone, did not significantly modify the action of S32504. In the nucleus accumbens, levels of 5-HT were only affected by the highest dose of S32504 (10.0 mg/kg, s.c.) (not shown). Area under the curve analysis was as follows: vehicle (n ϭ 8), ϩ1.2 Ϯ 2.2% versus S32504 (n ϭ 5), Ϫ40.3% Ϯ 4.2, F(1,11) ϭ 20.2, P Ͻ 0.01. Likewise, in the nucleus accumbens, 5-HT levels were only modified by the highest dose of ropinirole (10.0 mg/kg, s.c.) (not shown). Area under the curve analysis was as follows: vehicle (n ϭ 8), ϩ1.2 Ϯ 2.2 versus ropinirole (n ϭ 6), Ϫ16.0 Ϯ 3.6, F(1,12) ϭ 5.9, P Ͻ 0.05. In the striatum, the minimal dose of S32504 required to significantly diminish levels of 5-HT (2.5 mg/kg, s.c.) was 64-fold higher than the minimum dose needed to significantly suppress DA levels (0.04 mg/kg, s.c.) (Fig. 9) . The inhibitory influence of S32504 (10.0 mg/kg, s.c.) upon striatal levels of 5-HT was blocked in the presence of the selective 5-HT 1A receptor antagonist WAY100,635 (0.63 mg/kg, s.c.), which did not modify levels of 5-HT (not shown). Area under the curve analysis was as follows: vehicle/vehicle (n ϭ 7), Ϫ 4.0 Ϯ 2.4; vehicle/S32504 (n ϭ 5), Ϫ 42.7 Ϯ 2.2; WAY100,635/vehicle (n ϭ 5) ϩ1.6 Ϯ 2.9; and WAY100,635/S32504 (n ϭ 5) Ϫ 14.5 Ϯ 1.8; influence of WAY100,635, F(1,10) ϭ 1.1, P Ͼ 0.05; influence of S32504, F(1,10) ϭ 51.2, P Ͻ 0. 01; and interaction, F(1,8) ϭ 66.9, P Ͻ 0.01. The difference between WAY100,635/S32504 and vehicle/S32504 values was significant (P Ͻ 0.05) in Dunnett's test. The reduction by S32504 (10.0 mg/kg, s.c.) of striatal DA levels was not modified in the presence of WAY100,635 (0.63 mg/kg, s.c.) (not shown). By analogy to S32504, in the striatum, only a dose of ropinirole (10.0 mg/kg, s.c.) far higher than the minimal effective dose required to suppress DA levels significantly reduced levels of 5-HT (Fig. 9) .
Modulation of Cerebral Turnover of DA Compared with 5-HT. In terminal regions of mesocortical dopaminergic pathways (the FCX), mesolimbic dopaminergic pathways (the nucleus accumbens and olfactory tubercles), and the nigrostriatal dopaminergic pathway (the striatum), S32504 elicited a marked and dose-dependent reduction in the ratio of DA to DOPAC, indicative of a suppression in DA turnover. There was no marked or significant difference among the various structures concerning the potency and the magnitude of the suppressive influence of S32504, suggesting that its inhibitory influence upon mesocortical, mesolimbic, and nigrostriatal dopaminergic pathways is expressed to a similar degree. Ropinirole mimicked this inhibitory influence of S32504 upon DA to DOPAC ratios. S32504 and ropinirole exerted only a modest influence upon 5-HT turnover (as estimated by the ratio of 5-HT to its metabolite, 5-HIAA) even at doses higher than these reducing DA turnover. These observations underpin electrophysiological and dialysis studies outlined above, indicating that S32504 and ropinirole affect serotonergic pathways only at doses markedly higher than those influencing dopaminergic transmission (Fig. 12) .
Discussion
Receptor-Binding Profile of S32504: Marked Preference for hD 3 Receptors. S32504, the optically pure, (ϩ)isomer of racemic S31411, interacted stereospecifically and with high affinity at hD 3 receptors compared with its enantiomer S32601. This stereospecific pattern of recognition was also apparent at hD 2S and hD 2L receptors for which, however, the 
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affinity of S32504 was substantially lower. Notably, S32504 was a more potent ligand of hD 3 receptors than ropinirole from which it could also be distinguished by its high selectivity for hD 3 versus hD 4 receptors. Indeed, the weak stimulation of hD 4 receptors by S32504 differentiates it from numerous antiparkinsonian agents and is of significance inasmuch their activation does not contribute to improvement of motor function by antiparkinsonian agents and may even unfavorably influence mood and cognition (Oak et al., 2000; Newman-Tancredi et al., 2002a) . More generally, the high selectivity of S32504 for hD 3 receptors differentiates it from the majority of antiparkinsonian drugs that potently interact with various classes of ␣-adrenoceptor, 5-HT receptor, and/or histaminergic receptor Newman-Tancredi et al., 2002a,b ) (see below). Agonist Properties of S32504 at hD 3 Receptors: GProtein Recruitment. In line with its high affinity, in a [ 35 S]GTP␥S model of G-protein activation , S32504 manifested potent and robust agonist properties at hD 3 receptors compared with ropinirole ( Table 2 ). The efficacy of S32504 (74%) bears comparison to the constrained range of efficacies (39 -94%) of 14 antiparkinsonian agents examined under identical conditions . Employing an antibody neutralization strategy to uncouple hD 3 receptors from their respective G-proteins, we previously showed that CHOtransfected hD 3 receptors primarily couple to pertussis-sensitive G i/o proteins . Of this family, exploiting an innovative SPA/antibody-based strategy, we found herein that S32504 and ropinirole activate hD 3 receptor-coupled G␣ i3 , and the specificity of its engagement by S32504 was confirmed by blockade with haloperidol and the selective D 3 receptor antagonist S33084 (Millan et al., 2000a) . Employing other antibodies, S32504 (and DA) were found not to activate G o , G q , or G s in this hD 3 receptortransfected CHO cell line (not shown). However, hD 3 receptors couple in a cell-specific fashion to various G-protein subtypes, including G o and G z (Liu et al., 1999; Obadiah et al., 1999; Zaworski et al., 1999) , so it would be of interest to further evaluate G-protein recruitment by S32504 at hD 3 receptors in other systems.
Agonist Properties of S32504 at hD 3 Receptors: MAP Kinase Phosphorylation. Pertussis-sensitive G i/o -proteins transduce MAP kinase phosphorylation by hD 3 receptors , which was accordingly powerfully stimulated by S32504. Moreover, mimicking the SPA study, S33084 potently blocked S32504-induced MAP kinase phosphorylation with a potency close to its affinity for hD 3 receptors (Millan et al., 2000a) . Although less potent than S32504, ropinirole was also an efficacious agonist, complementing studies of its agonist properties employing measures of adenylyl cyclase, mitogenesis, and extracellular acidification (Coldwell et al., 1999; Perachon et al., 1999 ). The precise physiological significance of S32504-induced MAP kinase via hD 3 receptors remains to be clarified. However, this signal is jpet.aspetjournals.org implicated in the neuroprotective influence of S32504 and other dopaminergic agonists upon dopaminergic neurons that, as discussed in the accompanying paper (Millan et al., 2004b) and elsewhere (Joyce et al., 2003; Ramirez et al., 2003) , appear to involve the activation of dopamine D 3 receptors.
Agonist Properties of S32504 at hD 2S and hD 2L Receptors:
G-Protein Recruitment. Exploiting a [ 35 S]GTP␥S binding paradigm, S32504 behaved as an agonist at hD 2L and hD 2S receptors with, respectively, high and modest efficacy. Inasmuch as these observations are comparable to ropinirole and many other antiparkinsonian drugs , differential efficacy at hD 2L versus hD 2S sites may be an intrinsic feature of the cellular expression systems employed. Indeed, contrasting patterns of G-protein activation by hD 2L versus hD 2S receptors have been reported in certain other cell lines (Gardner et al., 1996; Picetti et al., 1997; Newman-Tancredi et al., 2002a) . Filtration assays do not permit identification of individual G-proteins, but in a novel SPA procedure, S32504 and ropinirole potently activated G␣ i3 via hD 2L sites. Employing a complementary strategy-cotransfection with mutant Gproteins resistant to pertussis toxin-O' Hara et al. (1996) also showed that hD 2L receptors recruit G␣ i3 . Using an antisense knockdown strategy, activation of G␣ i3 by hD 2L sites was likewise reported by Wolfe and Morris (1999) . However, it would be interesting to examine the influence of S32504 upon other species of G-protein known to couple to hD 2L and hD 2S receptors: notably, G o in neuronal tissue (Wolfe and Morris, 1999; Alberts et al., 2000; Cordeaux et al., 2001; Jiang et al., 2001; Watts et al., 2001) .
Agonist Properties of S32504 at hD 2L Receptors: MAP Kinase Phosphorylation. Pertussis-sensitive G i/oproteins are implicated in the induction of MAP kinase via hD 2L receptors (Choi et al., 1999; Oak et al., 2001) , and both S32504 and ropinirole robustly increased MAP kinase phosphorylation. These findings correspond to the high efficacy of S32504 and ropinirole for suppression of forskolin-stimulated adenylyl cyclase activity at hD 2L receptors (Maggio et al., 2003) . Furthermore, they complement observations of agonist properties of ropinirole at hD 2L (and hD 2S ) sites employing parameters of extracellular acidification and mitogenesis (Coldwell et al., 1999; Perachon et al., 1999) . Relative to G-protein coupling, there was a substantial potency shift for both S32504 and ropinirole in eliciting MAP kinase phosphorylation. This amplification of signaling is specific since: 1) identical shifts in potency are seen for other agonists at hD 2L sites (D. Cussac, unpublished observations); 2) S32601 did not stimulate MAP kinase phosphorylation (not shown); 3) the action of S32504 was abolished by haloperidol and L741,626 at doses similar to those blocking G i/o activation via hD 2L receptors; and 4) studies of other G-protein-coupled receptors, such as ␣ 2 -adrenoceptors and h5-HT 1A receptors, revealed comparable amplification between the G-protein and downstream effectors (Lopez-Ilasaca, 1998; Umland et al., 2001; . This marked amplification between G i/o -and MAP kinase at hD 2L but not hD 3 receptors likely reflects contrasting intracellular pathways for engagement of MAP kinase at hD 2L versus hD 3 sites (Luo et al., 1998; Welsh et al., 1998; Cussac et al., 1999; Oak et al., 2001) . Notably, in addition to G␣-subunits, hD 2L receptors may stimulate MAP kinase via G␤␥ subunit release and other components of the MAP kinase cascade such as Grb 2 and Shc (Hawes et al., 1995) . Irrespective of mechanisms underlying amplification, the potent and efficacious activation of hD 2L receptor-coupled MAP kinase by S32504, ropinirole, and other agonists provides a substrate for their pronounced actions at D 2 receptors in vivo (Levant, 1997; Picetti et al., 1997; Joyce, 2001; Millan et al., 2004a,b) . Furthermore, by analogy to other cellular signals downstream of G-proteins, the apparently pronounced preference of S32504 for hD 3 versus hD 2 receptors in binding and [
35 S]GTP␥S-binding studies is eclipsed at the level of MAP kinase (Coldwell et al., 1999; Cussac et al., 1999; Millan et al., 2000a) . Although the precise significance of MAP kinase to the ac- (Welsh et al., 1998; Cai et al., 2002) .
Activation by S32504 of D 2 /D 3 Autoreceptors. In line with other dopaminergic agonists such as ropinirole (Eden et al., 1991) , S32504 stereospecifically suppressed the activity of frontocortical, mesolimbic, and nigrostriatal dopaminergic pathways. Anatomical (Stanwood et al., 2000) , pharmacological (Millan et al., 2000a,b) , gene knockout (Sibley, 1999) , and antisense (Ekman et al., 1998) studies support a major role of D 2 sites in the modulation of dopaminergic transmission (Levant, 1997; Millan et al., 2000b) , and the D 2S isoform is principally involved (Centonze et al., 2002) . Indeed, the inhibitory influence of S32504 upon DA release in nucleus accumbens and striatum was resistant to S33084 yet abolished by haloperidol and L741,626, consistent with a key role of D 2 sites. Nevertheless, a possible role of D 3 receptors should not be entirely excluded. First, the facilitation by L741,626 and haloperidol of dopaminergic transmission complicates interpretation of their actions. Second, although we acquired an identical pattern of data employing a further D 3 antagonist, PD128,907, in interaction with L741,626 (blocked) and S33084 (refractory) (Millan et al., 2004c) , Taylor et al. (1999) observed an abrogation of the PD128,907-induced reduction of DA release in the nucleus accumbens, although not striatum, employing a further D 3 antagonist, SB269,652. Third, likewise using PD128,907, we have obtained evidence that D 3 receptors control DA release in the FCX (Millan et al., 2000a) . Fourth, studies in genetically modified mice suggest that, under certain conditions, terminal D 3 receptors modulate DA release (Zapata et al., 2001; Joseph et al., 2002) . Finally, via a Weak Agonist Actions of S32504 at h5-HT 1A and h5-HT 2A Receptors. It has been proposed that 5-HT 1A agonist properties are favorable for antiparkinsonian agents in improving mood and alleviating dyskinesias (Bibbiani et al., 2001) . Although this remains to be clinically proven, virtually all antiparkinsonian agents possess at least moderate partial agonist properties at 5-HT 1A receptors (NewmanTancredi et al., 2002b) . Indeed, like ropinirole, S32504 similarly showed mild potency and efficacy at h5-HT 1A sites in vitro. However, despite the high sensitivity of presynaptic 5-HT 1A receptors (Millan et al., 2000b) , S32504 and ropinirole reduced cerebral 5-HT release only at doses markedly higher than those that suppressed DA release. It is unlikely, then, that 5-HT 1A receptors make a major contribution to the functional actions of S32504 in vivo, an assertion underpinned by the lack of influence of 5-HT 1A receptor antagonists upon its behavioral actions (Millan et al., 2004b) . It has been suggested that engagement of 5-HT 2A receptors facilitates motor function in PD but, less favorably, exacerbates psychiatric side effects (Gresch and Walker, 1999; NewmanTancredi et al., 2002b) . Compared with the potent agonist properties at h5-HT 2A receptors of, for example, pergolide , S32504 behaved as a very weak agonist at G q and phospholipase C, prototypical transduction mechanisms coupled to 5-HT 2A receptors. It is unlikely, then, that they are involved in its actions.
General Comments. First, this study focuses on actions of S32504 at D 2 (D 3 ) autoreceptors, which likely participate in its anxiolytic and neuroprotective properties (Millan et al., 2004a,b) . S32504 also shows robust and potent agonist actions at postsynaptic D 2 /D 3 receptors mediating, for example, prolactin secretion and yawning (M. J. Millan, unpublished observations) . Activation of postsynaptic populations of D 2 (D 3 ) sites is implicated in the antiparkinsonian (motor) and antidepressant actions of S32504 (Millan et al., 2004a,b) . Second, D 3 and D 2 receptors are colocalized on dopaminergic and certain other classes of neuron (Stanwood et al., 2000; Joyce, 2001 ). Inasmuch as S32504 behaves as a potent and efficacious agonist at (Maggio et al., 2003) , certain functional actions attributed to D 3 or D 2 monomers might actually involve recruitment of D 2 /D 3 heterodimers. Third, as for all G-protein-coupled receptors, ligand efficacy at D 3 and D 2 receptors depends upon many factors, including the intracellular signal and cell line under study (Cordeaux et al., 2001; Cussac et al., 2002b) . Additional work will be required to more fully explore the influence of S32504 upon multiple coupling cascades at diverse populations of D 3 and D 2 receptors. Finally, for other dopaminergic ligands, the precise relationship between its cellular actions and its therapeutic properties awaits further clarification.
Conclusions. The novel naphtoxazine S32504 is a potent and highly selective agonist at hD 3 receptors and, reflecting signal amplification downstream of G-proteins, hD 2S and hD 2L receptors, whereas it is devoid of activity at hD 4 sites. This distinctive profile is associated with a potent inhibitory influence upon dopaminergic pathways. These observations provide a framework for the following papers (Millan et al., 2004a,b) demonstrating marked activity of S32504 in models of potential antiparkinsonian, neuroprotective, antidepressant, and anxiolytic properties. Influence of S32504 compared with ropinirole upon the turnover of dopamine (DA) and 5-HT in projection targets of frontocortical, mesolimbic, and nigrostriatal dopaminergic pathways. Data are means Ϯ S.E.M. n Ͼ 5 per value. Absolute levels of DOPAC/DA and ANOVA as follows: frontal cortex, DA ϭ 0.9 Ϯ 0.2 ng/mg protein and DOPAC ϭ 0.2 Ϯ 0.1 ng/mg protein; S32504, F(4,15) ϭ 13.5, P Ͻ 0.05; and ropinirole, F (3, 12) ϭ 34.8, P Ͻ 0.05; nucleus accumbens, DA ϭ 46.8 Ϯ 3.2 ng/mg protein and DOPAC ϭ 4.6 Ϯ 0.4 ng/mg protein; S32504, F(4,15) ϭ 14.7, P Ͻ 0.05; and ropinirole, F (3, 12) ϭ 178, P Ͻ 0.05; olfactory tubercles, DA ϭ 28.2 Ϯ 3.5 ng/mg protein and DOPAC ϭ 3.5 Ϯ 0.2 ng/mg protein; S32504, F(4,15) ϭ 44.1, P Ͻ 0.05; ropinirole, F (3, 12) ϭ 19.6, P Ͻ 0.05; striatum, DA ϭ 83.9 Ϯ 5.6 ng/mg protein and DOPAC ϭ 5.5 Ϯ 0.2 ng/mg protein; S32504, F(4,15) ϭ 20.9, P Ͻ 0.05; and ropinirole, F (3, 12) ϭ 168, P Ͻ 0.05. Absolute levels of 5-HIAA/5-HT and ANOVA as follows: frontal cortex, 5-HT ϭ 2.6 Ϯ 0.8 ng/mg protein and 5-HIAA ϭ 1.3 Ϯ 0.3 ng/mg protein; S32504, F(4,15) ϭ 0.8, P Ͼ 0.05; and ropinirole, F (3, 12 ) ϭ 1.8, P Ͼ 0.05; nucleus accumbens, 5-HT ϭ 2.6 Ϯ 0.8 ng/mg protein and 5-HIAA ϭ 1.3 Ϯ 0.3 ng/mg protein; S32504, F(4,15) ϭ 2.0, P Ͼ 0.05; and ropinirole, F (3, 12 ) ϭ 1.8, P Ͼ 0.05; olfactory tubercles, 5-HT ϭ 3.1 Ϯ 0.1 ng/mg protein and 5-HIAA ϭ 2.6 Ϯ 0.2 ng/mg protein; S32504, F(4,15) ϭ 1.5, P Ͼ 0.05 and ropinirole, F (3, 12) ϭ 7.0, P Ͻ 0.05 and striatum, 5-HT ϭ 3.1 Ϯ 0.1 ng/mg protein and 5-HIAA ϭ 2.6 Ϯ 0.2 ng/mg protein; S32504, F(4,15) ϭ 5.0, P Ͻ 0.05 and ropinirole, F (3, 12) ϭ 5.5, P Ͻ 0.05. Asterisks indicate significance of drug versus vehicle differences in Dunnett's test following ANOVA. ‫,ء‬ P Ͻ 0.05. 
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